ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Stock Price Down 1.7%

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)’s share price traded down 1.7% during mid-day trading on Thursday . The stock traded as low as $36.46 and last traded at $36.80. 9,494 shares were traded during trading, a decline of 22% from the average session volume of 12,146 shares. The stock had previously closed at $37.45.

ALPS Medical Breakthroughs ETF Trading Down 3.2 %

The firm’s 50-day moving average price is $34.75 and its 200-day moving average price is $34.50.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Phoenix Wealth Advisors boosted its stake in ALPS Medical Breakthroughs ETF by 11.5% during the fourth quarter. Phoenix Wealth Advisors now owns 10,938 shares of the company’s stock valued at $359,000 after buying an additional 1,130 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF in the fourth quarter valued at $518,000. Central Valley Advisors LLC bought a new stake in ALPS Medical Breakthroughs ETF in the first quarter worth $200,000. McGuire Investment Group LLC increased its position in ALPS Medical Breakthroughs ETF by 15.5% in the first quarter. McGuire Investment Group LLC now owns 8,550 shares of the company’s stock worth $306,000 after purchasing an additional 1,150 shares during the last quarter. Finally, DAVENPORT & Co LLC raised its stake in ALPS Medical Breakthroughs ETF by 12.1% during the first quarter. DAVENPORT & Co LLC now owns 771,189 shares of the company’s stock valued at $27,461,000 after purchasing an additional 83,403 shares in the last quarter.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.